ReviewJournal of clinical epidemiology2010
Expectations, validity, and reality in pharmacogenetics.
Review in Journal of clinical epidemiology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 48 citations in OpenAlex.
- Translational Pharmacogenomics: Discovery, Evidence Synthesis and Delivery of Race-Conscious Medicine.Clinical pharmacology and therapeutics · 2021Review
- The art and science of drug titration.Therapeutic advances in drug safety · 2020Review
- If you build it, they will come: unintended future uses of organised health data collections.BMC medical ethics · 2016Review
- Alcohol misuse, genetics, and major bleeding among warfarin therapy patients in a community setting.Pharmacoepidemiology and drug safety · 2015Article
- Pharmacogenomics in diverse practice settings: implementation beyond major metropolitan areas.Pharmacogenomics · 2015Article
- Genetic risk factors for major bleeding in patients treated with warfarin in a community setting.Clinical pharmacology and therapeutics · 2014Article
- The role of expectations, hype and ethics in neuroimaging and neuromodulation futures.Frontiers in systems neuroscience · 2014Review
- Genome-wide association studies in pharmacogenomics: successes and lessons.Pharmacogenetics and genomics · 2013Review
- Getting our priorities straight: a novel framework for stakeholder-informed prioritization of cancer genomics research.Genetics in medicine : official journal of the American College of Medical Genetics · 2013Article
- Building the evidence base for decision making in cancer genomic medicine using comparative effectiveness research.Genetics in medicine : official journal of the American College of Medical Genetics · 2012Review
- Warfarin pharmacogenetics: challenges and opportunities for clinical translation.Frontiers in pharmacology · 2012Article
- Statistical Optimization of Pharmacogenomics Association Studies: Key Considerations from Study Design to Analysis.Current pharmacogenomics and personalized medicine · 2011Article
- The emergence of translational epidemiology: from scientific discovery to population health impact.American journal of epidemiology · 2010Article
- Pharmacogenetics of drug hypersensitivity.Pharmacogenomics · 2010Review
- Genetic variations in human glutathione transferase enzymes: significance for pharmacology and toxicology.Human genomics and proteomics : HGP · 2010Article
- Commentary: Children and predictive genomic testing: disease prevention, research protection, and our future.Journal of pediatric psychologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
In this review, we discuss the potential expectations, validity, predictive ability, and reality of pharmacogenetics in (1) titration of medication dose, (2) prediction of intended (efficacy) drug response, and (3) dose prediction of unintended (adverse) drug response. We expound on what these potential genetic predictors tell us and, more importantly, what they cannot tell us. Although pharmacogenetic markers have been hailed as promising tools, these proclamations are based mainly on associations rather than their evaluation as predictors. To put the expectations of the promise of pharmacogenetics in a realistic perspective, we review three examples. First, warfarin pharmacogenetics, wherein although the validity of the genetic variant dose is established and there is a validity of genetic variant-hemorrhage association, the clinical utility of testing is not clear. Second, the strong and clinically relevant HLA-Stevens-Johnson syndrome/toxic epidermal necrolysis association highlights the role of ethnicity. Third, the influence of CYP2D6 on tamoxifen efficacy, a model candidate with potential clinical utility but unclear validity. These examples highlight both the challenges and opportunities of pharmacogenomics. First, establishing a valid association between a genetic variation and drug response; second, doing so for a clinically meaningful outcome; and third, providing solid evidence or rationale for improvement in patient outcomes compared with current standard of care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.